IL291979B2 - Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy - Google Patents

Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Info

Publication number
IL291979B2
IL291979B2 IL291979A IL29197922A IL291979B2 IL 291979 B2 IL291979 B2 IL 291979B2 IL 291979 A IL291979 A IL 291979A IL 29197922 A IL29197922 A IL 29197922A IL 291979 B2 IL291979 B2 IL 291979B2
Authority
IL
Israel
Prior art keywords
cancer
compound
cells
melanoma
pharmaceutically acceptable
Prior art date
Application number
IL291979A
Other languages
English (en)
Hebrew (he)
Other versions
IL291979B1 (en
IL291979A (en
Original Assignee
Cellectar Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Biosciences Inc filed Critical Cellectar Biosciences Inc
Publication of IL291979A publication Critical patent/IL291979A/en
Publication of IL291979B1 publication Critical patent/IL291979B1/en
Publication of IL291979B2 publication Critical patent/IL291979B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL291979A 2019-10-10 2020-10-09 Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy IL291979B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962913571P 2019-10-10 2019-10-10
PCT/US2020/055121 WO2021072300A1 (en) 2019-10-10 2020-10-09 Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Publications (3)

Publication Number Publication Date
IL291979A IL291979A (en) 2022-06-01
IL291979B1 IL291979B1 (en) 2025-08-01
IL291979B2 true IL291979B2 (en) 2025-12-01

Family

ID=75436788

Family Applications (1)

Application Number Title Priority Date Filing Date
IL291979A IL291979B2 (en) 2019-10-10 2020-10-09 Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Country Status (11)

Country Link
US (1) US12496346B2 (cg-RX-API-DMAC7.html)
EP (1) EP4041718A4 (cg-RX-API-DMAC7.html)
JP (1) JP7631329B2 (cg-RX-API-DMAC7.html)
KR (1) KR102973364B1 (cg-RX-API-DMAC7.html)
CN (1) CN114761389B (cg-RX-API-DMAC7.html)
AU (1) AU2020361679B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022006739B1 (cg-RX-API-DMAC7.html)
CA (1) CA3154192A1 (cg-RX-API-DMAC7.html)
IL (1) IL291979B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022004341A (cg-RX-API-DMAC7.html)
WO (1) WO2021072300A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019200017A1 (en) * 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
KR102973364B1 (ko) 2019-10-10 2026-06-04 셀렉타 바이오사이언시스, 인코퍼레이티드 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법
WO2025073824A1 (en) * 2023-10-03 2025-04-10 Aarhus Universitet Phospholipid conjugates and their uses

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965391A (en) 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
DE4132344A1 (de) 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
DE4408011C1 (de) 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie
WO1998024480A1 (en) 1996-12-04 1998-06-11 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
WO2006014589A2 (en) 2004-07-08 2006-02-09 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
DE602005015687D1 (de) 2004-03-02 2009-09-10 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
US7632644B2 (en) 2004-03-02 2009-12-15 Cellectar, Inc. Imaging and selective retention of phospholipid ether analogs
MX2007007497A (es) 2004-12-20 2008-01-11 Cellectar Llc Analogos de fosfolipido eter para la deteccion y tratamiento del cancer.
US20070167408A1 (en) 2005-12-19 2007-07-19 Zentaris Gmbh Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
US7893286B2 (en) 2007-06-01 2011-02-22 Cellectar, Inc. Method for the synthesis of phospholipid ethers
US8022235B2 (en) 2007-06-01 2011-09-20 Cellectar, Inc. Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use
CN101878024B (zh) 2007-11-28 2014-04-09 塞拉特药物股份有限公司 改良的紫杉烷递送系统
US20100120727A1 (en) * 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
US20100286510A1 (en) 2009-05-11 2010-11-11 Pinchuk Anatoly Use of fluorescent phospholipid ether compounds in biopsies
WO2010132428A1 (en) 2009-05-11 2010-11-18 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
US8871181B2 (en) 2009-05-11 2014-10-28 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
US7811548B1 (en) 2009-05-11 2010-10-12 Cellectar, Inc. Fluorescent phospholipid ether compounds and compositions
DK3708192T3 (da) * 2009-06-12 2023-11-06 Cellectar Inc Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
WO2011031919A2 (en) 2009-09-11 2011-03-17 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
US20140255432A1 (en) * 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
WO2014106826A2 (en) 2013-01-07 2014-07-10 Piramal Enterprises Limited Anthracycline analogue and uses thereof
FR3023290B1 (fr) 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
SG11201701565PA (en) 2014-09-03 2017-03-30 Immunogen Inc Conjugates comprising cell-binding agents and cytotoxic agents
CN107708702A (zh) * 2014-11-17 2018-02-16 塞勒克塔生物科学有限公司 磷脂醚类似物作为靶向癌症的药物载体
KR102934754B1 (ko) 2015-11-25 2026-03-04 이펙터 테라퓨틱스, 인크. Eif4a-억제 화합물 및 이에 관련된 방법
CN109310702A (zh) 2016-05-20 2019-02-05 芝加哥大学 用于化学疗法、靶向疗法、光动力疗法、免疫疗法和它们的任何组合的纳米颗粒
JP7043425B2 (ja) * 2016-06-06 2022-03-29 ジェネンテック, インコーポレイテッド シルベストロール抗体-薬物コンジュゲート及び使用方法
CN109791152B (zh) 2016-06-14 2023-03-03 塞勒科塔生物科学公司 用于鉴定和分离循环肿瘤细胞的磷脂醚类似物
KR20200015540A (ko) 2017-05-10 2020-02-12 인사이클 세라퓨틱스, 인코포레이티드 α4β7 인테그린을 타겟팅하는 호모데틱 사이클릭 펩타이드
CA3086454A1 (en) 2017-09-26 2019-04-04 National University Corporation Chiba University Radioactive drug
EP3749317A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES
WO2019200017A1 (en) 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
CA3097101A1 (en) 2018-04-16 2019-10-24 Nihon Medi-Physics Co., Ltd. Modified antibody and radioactive metal-labelled antibody
MX2022003044A (es) * 2019-09-12 2022-06-02 Cellectar Biosciences Inc Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.
KR102973364B1 (ko) 2019-10-10 2026-06-04 셀렉타 바이오사이언시스, 인코퍼레이티드 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법

Also Published As

Publication number Publication date
IL291979B1 (en) 2025-08-01
IL291979A (en) 2022-06-01
JP2022551495A (ja) 2022-12-09
CN114761389B (zh) 2025-02-07
EP4041718A4 (en) 2023-12-20
US20240325545A1 (en) 2024-10-03
AU2020361679A1 (en) 2022-04-28
EP4041718A1 (en) 2022-08-17
AU2020361679B2 (en) 2026-03-19
CN114761389A (zh) 2022-07-15
CA3154192A1 (en) 2021-04-15
KR20220080139A (ko) 2022-06-14
MX2022004341A (es) 2022-08-10
US12496346B2 (en) 2025-12-16
WO2021072300A1 (en) 2021-04-15
BR112022006739A2 (pt) 2022-06-28
BR112022006739B1 (pt) 2024-01-23
KR102973364B1 (ko) 2026-06-04
JP7631329B2 (ja) 2025-02-18

Similar Documents

Publication Publication Date Title
AU2020361679B2 (en) Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
AU2020346898B2 (en) Phospholipid ether conjugates as cancer-targeting drug vehicles
TW202426456A (zh) 新穎的喜樹鹼類似物及其免疫綴合物
AU2021261949A1 (en) Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
AU2022246090A1 (en) Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents
EA047198B1 (ru) Конъюгаты фосфолипид-флаваглин и способы их применения для нацеленной противораковой терапии
CA3236944A1 (en) Novel auristatin analogs and immunoconjugates thereof
JP2025500404A (ja) 新規オーリスタチン類似体およびその免疫複合体
HK40043232B (en) Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
HK40043232A (en) Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
EP4687996A1 (en) Antibody-drug conjugates and uses thereof
EA053296B1 (ru) Конъюгаты простого эфира фосфолипида в качестве носителей лекарственного средства для нацеливания на рак
TR202016160T (tr) Fosfoli̇pi̇d-flavagli̇n konjügeleri̇ ve bunlarin hedefe yöneli̇k
EA046205B1 (ru) Конъюгаты фосфолипид-флаваглин и способы их применения для целенаправленной терапии рака